Case Details
- Citation: [2012] SGHC 16
- Case Number: Suit No 416 of 2011 (Summons 5001/2011/M)
- Decision Date: 19 January 2012
- Tribunal/Court: High Court of the Republic of Singapore
- Coram: Chan Wei Sern Paul AR
- Plaintiff/Applicant: AstraZeneca AB (SE)
- Defendant/Respondent: Sanofi-Aventis Singapore Pte Ltd
- Counsel for Plaintiff: Lee Ai Ming, Alvin Lim and Sandeep Menon (Rodyk & Davidson LLP)
- Counsel for Defendant: Vignesh Vaerhn, Eunice Lim and Tan Lijun (Allen & Gledhill LLP)
- Legal Areas: Patents and Inventions – Infringement; Civil Procedure – Pleadings – Striking Out
- Statutes Referenced: Medicines Act (Cap 176, 1985 Rev Ed); Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed); Patents Act (Cap 221, 2005 Rev Ed) (contextual reference)
- Key Statutory Provision at Issue: Section 12A of the Medicines Act
- Patent at Issue: Singapore Patent No. 89993 (“Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor”)
- Judgment Length: 15 pages, 8,230 words
- Reported/Unreported: Reported (SGHC)
Summary
This High Court decision concerns the interaction between Singapore’s patent regime and the medicines licensing framework, specifically the “linkage” mechanism introduced by section 12A of the Medicines Act. AstraZeneca, the proprietor of Singapore Patent No. 89993, sought to restrain Sanofi-Aventis from proceeding with product licence applications for rosuvastatin calcium-containing products (Rosucard tablets) by relying on section 12A. The practical effect of AstraZeneca’s action was to trigger a 30-month stay on the processing of Sanofi’s product licence applications by the Health Sciences Authority (“HSA”).
Sanofi applied to strike out AstraZeneca’s amended Statement of Claim on the grounds that it disclosed no reasonable cause of action, was frivolous or vexatious, and/or constituted an abuse of process. The court’s analysis focused on whether section 12A creates an independent cause of action that permits a patentee to sue without any pleaded or evidenced infringement, and whether AstraZeneca’s pleadings were sufficiently particularised to support the relief sought.
Ultimately, the court granted Sanofi’s application and struck out AstraZeneca’s claim. The decision underscores that section 12A is not a substitute for the substantive requirements of patent infringement, and that a patentee cannot rely on mere assertions or disbelief of the defendant’s non-infringement position to sustain proceedings where the pleaded case lacks the necessary factual foundation.
What Were the Facts of This Case?
AstraZeneca AB (SE) is a pharmaceutical company incorporated in Sweden. Sanofi-Aventis Singapore Pte Ltd is a Singapore company engaged in research, development, manufacture and commercialisation of healthcare products. AstraZeneca is the owner of Singapore Patent No. 89993, titled “Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor.” The invention, as reflected in claim 5 of the patent specification, comprises (i) an active ingredient—rosuvastatin calcium—and (ii) a stabilising agent described as “an inorganic salt in which the cation is multivalent.” The stabiliser element was central to AstraZeneca’s infringement theory.
On 1 April 2011, Sanofi applied to the HSA for product licences for three strengths of Rosucard film-coated tablets: 10 mg, 20 mg and 40 mg (collectively, the “Proposed Products”). Under section 5 of the Medicines Act, product licences are required for selling, supplying, exporting, or procuring the manufacture/assembly of medicinal products for those purposes. In its application forms, Sanofi disclosed that a patent was in force in respect of the Proposed Products, that it was not the patent proprietor, and that the proprietor had not consented to or acquiesced in the grant of product licences. Sanofi also stated, in its opinion and to the best of its belief, that the patent would not be infringed by the acts for which the licences were sought.
Following HSA’s request, Sanofi served a notice on AstraZeneca using the prescribed form under the Medicines (Licensing, Standard Provisions and Fees) Regulations. The notice informed AstraZeneca that Sanofi had applied for product licences and that, unless AstraZeneca applied to court within 45 days for an order restraining the act or for a declaration of infringement, the HSA could proceed to grant the licence. AstraZeneca applied within the 45-day period, thereby invoking the statutory mechanism in section 12A(5) of the Medicines Act and regulation 5B(3) of the Regulations, which provides for a 30-month stay on processing the product licence applications.
AstraZeneca commenced proceedings by filing a Statement of Claim on 10 June 2011. There was some dispute about whether the action was commenced within the 45-day period, but the court indicated that this was not material for the present striking-out application. AstraZeneca later amended its Statement of Claim (Amendment No. 1). In the amended pleading, AstraZeneca sought declarations that Sanofi’s acts in Singapore would infringe the patent and sought an injunction restraining Sanofi from infringing the patent. Notably, AstraZeneca conceded that it had no evidence that Sanofi had already committed any act of infringement; the only act Sanofi had done in Singapore was to apply for product licences.
What Were the Key Legal Issues?
The first key issue was whether AstraZeneca’s amended Statement of Claim disclosed a reasonable cause of action. This required the court to consider the scope and effect of section 12A of the Medicines Act. AstraZeneca’s position was that section 12A provides a separate and independent cause of action enabling a patentee to test the possibility of future infringement on the assumption that the defendant will carry out the acts for which product licences are sought. Sanofi’s position was that section 12A is merely a notification mechanism and does not create an independent civil cause of action separate from patent infringement proceedings under the Patents Act.
A second issue was whether AstraZeneca’s pleadings were sufficiently grounded in factual allegations to sustain the claim. AstraZeneca did not plead particulars of infringement and did not file an affidavit in response to Sanofi’s striking-out application. The court therefore had to assess whether AstraZeneca’s case amounted to a pre-emptive challenge based on disbelief of Sanofi’s non-infringement explanation, without any pleaded or evidenced basis for concluding that the Proposed Products would contain the claimed stabiliser feature—“an inorganic salt in which the cation is multivalent.”
A third, related issue concerned abuse of process and the proper use of the court’s procedures. Sanofi argued that the action was not bona fide and was essentially designed to obtain the 30-month stay, and alternatively to obtain confidential information about the Proposed Products through discovery. The court had to decide whether the pleadings were frivolous or vexatious or otherwise an abuse of process.
How Did the Court Analyse the Issues?
The court began by setting out the legal framework for striking out pleadings under the Rules of Court. While the judgment extract provided is truncated, the court’s approach was clear: striking out is an exceptional remedy, but it is available where a pleading discloses no reasonable cause of action, is frivolous or vexatious, or constitutes an abuse of process. The court emphasised that the standard for striking out is not disputed and focused on applying that standard to the substance of AstraZeneca’s pleading.
On the substantive patent linkage question, the court considered the parties’ competing characterisations of section 12A. Sanofi relied on the logic that patent infringement actions require at least one instance of infringement, and that without any past infringement, proceedings under the Patents Act would fail. Sanofi also invoked the authority of Upjohn v Kerfoot ([1988] FSR 1), which supports the proposition that applying for regulatory licences is not itself an infringing act. Sanofi therefore argued that AstraZeneca’s claim could not be sustained because there was no infringement to anchor the relief sought.
AstraZeneca, however, clarified that it was not bringing a patent infringement action under the Patents Act. It argued that section 12A allows a patentee to obtain a court determination about infringement in the context of medicines licensing, effectively permitting a “future infringement” assessment. AstraZeneca’s theory was that the court should assume that Sanofi would carry out the acts for which the licences were sought, and then determine whether those acts would infringe the patent. AstraZeneca further argued that it was impossible, in practice, to use rosuvastatin calcium without using a stabiliser that falls within the patent claim, and that discovery could be used to reveal the exact composition of the Proposed Products.
The court’s analysis turned on the sufficiency of AstraZeneca’s pleading and the absence of factual foundation. The court noted that AstraZeneca conceded it had no evidence of infringement and that no particulars of infringement were filed. The court also observed that AstraZeneca’s amended Statement of Claim appeared to rely on a broad allegation that Sanofi’s acts “will infringe claims 1 to 27” if carried out, without identifying how the Proposed Products would meet each essential element of the patent claims. In particular, the stabiliser feature was the crux of the invention, yet AstraZeneca did not plead any concrete basis for concluding that Sanofi’s stabiliser would be “an inorganic salt in which the cation is multivalent.”
In assessing AstraZeneca’s reliance on section 12A, the court effectively treated the provision as enabling a procedural linkage to the patent system rather than eliminating the need for a coherent infringement case. Even if section 12A permits a patentee to seek relief in advance of actual commercial acts, the court still required a pleading that discloses a reasonable basis for infringement. A patentee cannot simply assert that the defendant’s product “must” infringe, or that it is “impossible” for the defendant to avoid the claimed feature, without pleading the factual basis for that assertion. The court also rejected the idea that discovery could cure a deficient pleading at the outset; discovery is not a substitute for the requirement to plead a case that is properly arguable on its face.
Finally, the court addressed the broader procedural concerns. AstraZeneca’s action, as presented, was closely tied to obtaining the 30-month stay. While the statutory scheme contemplates that a patentee may act within the prescribed time to prevent the HSA from granting a licence, the court was alert to the risk of using the mechanism as a tactical tool rather than a genuine infringement challenge. The absence of particulars, the lack of evidence, and the failure to respond with affidavit material all contributed to the conclusion that the claim was not bona fide in the sense required to survive a striking-out application.
What Was the Outcome?
The High Court granted Sanofi’s summons and struck out AstraZeneca’s amended Statement of Claim. In practical terms, AstraZeneca’s attempt to secure a declaration of infringement and an injunction through the section 12A mechanism failed at the pleadings stage.
The decision therefore removed the procedural advantage AstraZeneca sought—namely, the continuation of the 30-month stay on the processing of Sanofi’s product licence applications—because the underlying claim could not proceed.
Why Does This Case Matter?
AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd ([2012] SGHC 16) is significant for practitioners because it clarifies that section 12A of the Medicines Act, while designed to implement patent–medicines linkage obligations, does not dispense with the need for a properly pleaded and arguable infringement case. The decision signals that a patentee must do more than express disbelief of the defendant’s non-infringement position or rely on broad assertions about product composition. The court expects a coherent infringement theory tied to the essential elements of the patent claims.
For pharmaceutical patent litigation, the case is also a cautionary example about the limits of pre-emptive litigation. Even where the statutory scheme contemplates action before regulatory approval, the court will scrutinise whether the pleading discloses a reasonable cause of action and whether the claim is genuinely directed at infringement rather than functioning as a mechanism to delay market entry. Lawyers should therefore ensure that pleadings under section 12A include sufficient factual allegations and, where appropriate, particulars that explain why the defendant’s product is alleged to fall within the claim scope.
From a civil procedure perspective, the case reinforces the importance of responding to striking-out applications with appropriate evidence where necessary. AstraZeneca did not file an affidavit in response, and the court’s willingness to strike out reflects the procedural reality that courts will not allow speculative or underparticularised claims to proceed to discovery as a fishing expedition.
Legislation Referenced
- Medicines Act (Cap 176, 1985 Rev Ed), in particular section 12A
- Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed), in particular regulation 5B(3) and the Sixth Schedule notice procedure
- Patents Act (Cap 221, 2005 Rev Ed), sections 66 and 67 (contextual discussion)
Cases Cited
- [1988] FSR 1 — The Upjohn Company v T. Kerfoot & Co. Ltd
- [2002] SGHC 238
- [2012] SGHC 16
Source Documents
This article analyses [2012] SGHC 16 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.